+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 0Years - 18Years
All Genders
ID07022834

Study of Dabrafenib or Trametinib Combined with Clofarabine for Treating High-Risk, Recurrent, or Resistant Langerhans Cell Histiocytosis in Children

Led by West China Second University Hospital · Updated on 2025-06-15

20

Participants Needed

1

Research Sites

104 weeks

Total Duration

AI-Summary

What This Trial Is About

Langerhans cell histiocytosis LCH is a rare inflammatory tumor mostly affecting children, with symptoms ranging from mild to severe organ involvement. High-risk cases, involving liver, spleen, or blood system, have poorer outcomes and a higher chance of disease returning or progressing despite standard treatments like prednisone and vinblastine. Newer treatments such as cladribine and MAPK inhibitors have improved survival, but many patients still face challenges with disease resistance and recurrence. This study evaluates the combination of dabrafenib or trametinib both MAPK inhibitors with clofarabine, a chemotherapy drug, in children with high-risk, recurrent, or refractory LCH. Dabrafenib is given at 3-5 mgkgday or trametinib at 0.025 mgkgday, while clofarabine is administered as consolidation therapy at 25 mgm2day for 5 days and maintenance therapy at 25 mgm2day for 2 days. The trial aims to determine the safety and effectiveness of this combined treatment approach in these pediatric patients. Participants will be monitored for disease progression, treatment response, and side effects over time. The primary outcome is progression-free survival at 24 months, with secondary measures including overall response rates at 3 months and assessment of adverse events over 18 months. Children will undergo regular evaluations to track treatment impact and safety, with follow-up continuing to assess long-term outcomes throughout the study period ending in 2030.

CONDITIONS

Brief Title

Real-world Study of Darafenib or Trametinib and Clofarabine for High-risk/Recurrent/Refractory Langerhans Cell Histiocytosis in Children

Research Team

X

Xue Tang, MD

X

Xia Guo, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here